Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 230

1.

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.

Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M.

Hepatology. 2013 Apr;57(4):1407-15. doi: 10.1002/hep.25956. Epub 2013 Feb 11.

PMID:
22890726
[PubMed - indexed for MEDLINE]
2.

A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma.

Wege H, Brümmendorf TH, Gambacorti-Passerini C.

Hepatology. 2013 Apr;57(4):1291-3. doi: 10.1002/hep.26050. Epub 2013 Mar 14. No abstract available.

PMID:
22961818
[PubMed - indexed for MEDLINE]
3.

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.

Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.

Hepatology. 2013 May;57(5):1847-57. doi: 10.1002/hep.26224. Epub 2013 Mar 14.

PMID:
23299930
[PubMed - indexed for MEDLINE]
4.

Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.

Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, Zhu XD, Xu HX, Kong LQ, Wu WZ, Wang L, Song TQ, Li Q, Tang ZY.

Gastroenterology. 2012 Dec;143(6):1641-1649.e5. doi: 10.1053/j.gastro.2012.08.032. Epub 2012 Aug 23.

PMID:
22922424
[PubMed - indexed for MEDLINE]
5.

Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.

Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F.

Mol Cancer Ther. 2012 Oct;11(10):2284-93. doi: 10.1158/1535-7163.MCT-12-0093. Epub 2012 Aug 17.

PMID:
22902857
[PubMed - indexed for MEDLINE]
Free Article
6.

[Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].

Shen HJ, Wang YH, Xu J.

Zhonghua Zhong Liu Za Zhi. 2013 Feb;35(2):98-102. doi: 10.3760/cma.j.issn.0253-3766.2013.02.005. Chinese.

PMID:
23714662
[PubMed - indexed for MEDLINE]
7.

High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.

Zaharieva BM, Simon R, Diener PA, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Wilber K, Hering F, Schönenberger A, Flury R, Jäger P, Fehr JL, Mihatsch MJ, Gasser T, Sauter G, Toncheva DI.

J Pathol. 2003 Dec;201(4):603-8.

PMID:
14648664
[PubMed - indexed for MEDLINE]
8.

Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.

Savić R, He X, Fiel I, Schuchman EH.

PLoS One. 2013 May 28;8(5):e65620. doi: 10.1371/journal.pone.0065620. Print 2013.

PMID:
23724146
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.

Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF.

Cell Death Dis. 2013 Feb 7;4:e485. doi: 10.1038/cddis.2013.18.

PMID:
23392173
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.

Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY, Chao Y.

Int J Cancer. 2013 May 15;132(10):2448-58. doi: 10.1002/ijc.27925. Epub 2012 Nov 28.

PMID:
23129123
[PubMed - indexed for MEDLINE]
11.

Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.

Godin C, Dupont S, Ezzoukhry Z, Louandre C, Chatelain D, Henaut L, Sabbagh C, Regimbeau JM, Maziere JC, Barbare JC, Chauffert B, Galmiche A.

Anticancer Res. 2013 Apr;33(4):1415-20.

PMID:
23564781
[PubMed - indexed for MEDLINE]
12.

Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.

Personeni N, Rimassa L, Pressiani T, Destro A, Ligorio C, Tronconi MC, Bozzarelli S, Carnaghi C, Di Tommaso L, Giordano L, Roncalli M, Santoro A.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1179-87. doi: 10.1007/s00432-013-1429-x. Epub 2013 Apr 9.

PMID:
23568548
[PubMed - indexed for MEDLINE]
13.

Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.

Zhai JM, Yin XY, Lai YR, Hou X, Cai JP, Hao XY, Liang LJ, Zhang LJ.

Cancer Chemother Pharmacol. 2013 May;71(5):1255-64. doi: 10.1007/s00280-013-2120-2. Epub 2013 Feb 23.

PMID:
23435877
[PubMed - indexed for MEDLINE]
14.

Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.

Zhang QB, Sun HC, Zhang KZ, Jia QA, Bu Y, Wang M, Chai ZT, Zhang QB, Wang WQ, Kong LQ, Zhu XD, Lu L, Wu WZ, Wang L, Tang ZY.

PLoS One. 2013;8(2):e55945. doi: 10.1371/journal.pone.0055945. Epub 2013 Feb 8.

PMID:
23409093
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A.

Neoplasia. 2013 Oct;15(10):1161-71.

PMID:
24204195
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.

Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6. doi: 10.1097/MEG.0b013e328359e550. Review.

PMID:
23044808
[PubMed - indexed for MEDLINE]
17.

Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.

Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW, Chen KF.

Hepatology. 2014 Jan;59(1):190-201. doi: 10.1002/hep.26640. Epub 2013 Dec 9.

PMID:
23908138
[PubMed - indexed for MEDLINE]
18.

Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.

Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, Yano H.

Int J Oncol. 2013 Jun;42(6):1897-903. doi: 10.3892/ijo.2013.1904. Epub 2013 Apr 16.

PMID:
23588838
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.

Xu M, Xie XH, Xie XY, Xu ZF, Liu GJ, Zheng YL, Huang GL, Wang W, Zheng SG, Lü MD.

Acta Radiol. 2013 Mar 1;54(2):199-204. doi: 10.1258/ar.2012.120249. Epub 2012 Nov 21.

PMID:
23171528
[PubMed - indexed for MEDLINE]
20.

Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.

Kwon JH, Lee N, Park JY, Yu YS, Kim JP, Shin JH, Kim DS, Joh JW, Kim DS, Choi KY, Kang KJ, Kim G, Moon YH, Wang HJ.

PLoS One. 2013 Jun 13;8(6):e64260. doi: 10.1371/journal.pone.0064260. Print 2013.

PMID:
23785399
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk